tat nr2baa

Tat-NR2BAA is an inactive control peptide of Tat-NR2B9c. It shares a similar sequence with Tat-NR2B9c, but possesses a double-point mutation in the COOH terminal tSXV motif. This mutation renders Tat-NR2BAA unable to bind PSD-95. Tat-NR2B9c, on the other hand, is a membrane-permeable peptide that interferes with PSD-95/NMDAR binding. This interference leads to the decoupling of NR2B- and/or NR2A-type NMDARs from PSD-95[1][2].

Tat-NR2BAA TFA serves as the inactive control peptide for Tat-NR2B9c, featuring a comparable sequence with a crucial distinction: a double-point mutation in its COOH-terminal tSXV motif. This alteration renders Tat-NR2BAA TFA unable to bind to PSD-95, in contrast to Tat-NR2B9c. The latter is a membrane-permeant peptide that impedes PSD-95/NMDAR interaction, specifically detaching NR2B- and/or NR2A-type NMDARs from PSD-95 [1].

TAT-P4-(DATC5)2 TFA, a high-affinity peptide inhibitor targeting the PDZ domain of protein interacting with C kinase-1 (PICK1), exhibits a K i of 1.7 nM and demonstrates potential in mitigating addiction behaviors in rats [1].

TAT-P4-(DATC5)2 is a potent peptide inhibitor targeting the PDZ domain of protein interacting with C kinase-1 (PICK1), exhibiting a high affinity with a dissociation constant (K_i) of 1.7 nM. This compound has demonstrated the capacity to mitigate addiction behaviors in rat models [1].

This peptide is a scrambled sequence of NADPH oxidase assembly peptide inhibitor gp91 ds-tat. It is used as a control peptide. It is two amino acid residues shorter at the N-terminus compared to the scrambled gp91 ds-tat.

TAT 2-4 is a peptide derived from HIV-1 transactivator of transcription (Tat) protein.The HIV Tat-derived peptide is a small basic peptide that has been successfully shown to deliver a large variety of cargoes, from small particles to proteins, peptides a